UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
of
the Securities Exchange Act of 1934
For
the
month of October 2008
Commission
File Number: 000-51310
XTL
Biopharmaceuticals Ltd.
(Translation
of registrant's name into English)
711
Executive Blvd., Suite Q
Valley
Cottage, New York 10989
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F.
Form
20-F
X
Form
40-F
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7): ____
Indicate
by check mark whether by furnishing the information contained in this Form,
the
registrant is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes
___ No
X
If
“Yes”
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82-
N/A
XTL
Biopharmaceuticals Extraordinary General Meetings Postponed Until October 10,
2008
Valley
Cottage, New York, October 2, 2008
- XTL
Biopharmaceuticals Ltd. (NASDAQ: XTLB; TASE: XTL) today announced that its
Extraordinary General Meetings (“EGMs”) were postponed until October 10, 2008 in
accordance with its articles of association due to the absence of a quorum.
The
postponed EGMs will take place at the offices of Kantor & Co. Law Offices,
14 Abba Hillel Silver Road, Oz House, 12th Floor, Ramat Gan, Israel at 3:00
p.m.
Israel time, and 5:30 p.m. Israel time, respectively, on October 10, 2008.
Any
proxy
votes received at any time up to 48 hours prior to the postponed EGMs will
be
included in the total votes counted for the EGMs. Those shareholders who have
a
valid “proof of ownership” in Israel or a letter of representation from
Computershare, the Company’s United Kingdom registrars, and attend the meeting
in person will also be permitted to vote.
ABOUT
XTL BIOPHARMACEUTICALS LTD.
XTL
Biopharmaceuticals Ltd. (“XTL”) is engaged in the development of therapeutics
for the treatment of diabetic neuropathic pain and HCV. XTL is developing
Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment
of diabetic neuropathic pain, which is currently in a Phase 2b study. XTL has
out-licensed its novel pre-clinical HCV small molecule inhibitor program. XTL
also has an active in-licensing and acquisition program designed to identify
and
acquire additional drug candidates. XTL is publicly traded on the NASDAQ and
Tel-Aviv Stock Exchanges (NASDAQ: XTLB; TASE: XTL).
Contact:
Ron
Bentsur, Chief Executive Officer
Tel:
+1-(845)-267-0707 ext. 225
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
| XTL BIOPHARMACEUTICALS LTD. | ||
| |
|
|
| Date: October 2, 2008 | By: | /s/ Ron Bentsur |
|
Ron Bentsur |
||
|
Chief
Executive
Officer
|
||